BiDil, a drug that combats congestive heart failure by dilating the arteries and veins, was approved in 2005 as a treatment for African-Americans only. There is no firm evidence that BiDil works better for African-Americans than for whites.

BiDil is a combination of two generic pills that are available at one-sixth the cost of the patented drug.

Although BiDil may delay hospitalization and death for heart failure patients, the race-specific approval of the drug sets an unwise precedent.
—The Editors